;PMID: 9799749
;source_file_1389.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:38..195] = [t:38..195]
;2)section:[e:199..306] = [t:199..306]
;3)section:[e:310..436] = [t:310..436]
;4)sentence:[e:440..523] = [t:440..523]
;5)sentence:[e:524..862] = [t:524..862]
;6)sentence:[e:863..919] = [t:863..919]
;7)sentence:[e:920..1069] = [t:920..1069]
;8)sentence:[e:1070..1177] = [t:1070..1177]
;9)sentence:[e:1178..1252] = [t:1178..1252]
;10)sentence:[e:1253..1413] = [t:1253..1413]
;11)section:[e:1417..1461] = [t:1417..1461]

;section 0 Span:0..33
;Clin Chem  1998 Nov;44(11):2243-8
(SEC
  (FRAG (DT:[0..4] Clin) (JJ:[5..9] Chem) (CD:[11..15] 1998)
        (CD:[16..23] Nov;44-LRB-) (CD:[23..25] 11) (-RRB-:[25..26] -RRB-)
        (CD:[26..31] :2243) (::[31..32] -) (CD:[32..33] 8)))

;sentence 1 Span:38..195
;K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic 
;masses: prospective study using two techniques with different detection
;limits.
;[38..43]:gene-rna:"K-ras"
;[104..122]:malignancy:"pancreatic  masses"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[38..43] K-ras) (NN:[44..48] gene) (NNS:[49..58] mutations))
      (PP (IN:[59..61] in)
        (NP
          (NP (DT:[62..65] the) (NN:[66..75] diagnosis))
          (PP (IN:[76..78] of)
            (NP
              (NP
                (NML (JJ:[79..83] fine) (HYPH:[83..84] -) (NN:[84..90] needle))
                (NNS:[91..100] aspirates))
              (PP (IN:[101..103] of)
                (NP (JJ:[104..114] pancreatic) (NNS:[116..122] masses))))))))
    (::[122..123] :)
    (NP
      (NP (JJ:[124..135] prospective) (NN:[136..141] study))
      (VP (VBG:[142..147] using)
        (NP
          (NP (CD:[148..151] two) (NNS:[152..162] techniques))
          (PP (IN:[163..167] with)
            (NP (JJ:[168..177] different) (NN:[178..187] detection)
                (NNS:[188..194] limits))))))
    (.:[194..195] .)))

;section 2 Span:199..306
;Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E, Gonzalez-Sastre F,
; Lluis F, Farre A, Capella G.
(SEC
  (FRAG (NNP:[199..203] Mora) (NNP:[204..206] J,) (NNP:[207..211] Puig)
        (NNP:[212..213] P) (,:[213..214] ,) (NNP:[215..221] Boadas)
        (NNP:[222..224] J,) (NNP:[225..231] Urgell) (NNP:[232..233] E)
        (,:[233..234] ,) (NNP:[235..245] Montserrat) (NNP:[246..247] E)
        (,:[247..248] ,) (NNP:[249..254] Lerma) (NNP:[255..256] E)
        (,:[256..257] ,) (NNP:[258..266] Gonzalez) (HYPH:[266..267] -)
        (JJ:[267..273] Sastre) (NNP:[274..275] F) (,:[275..276] ,)
        (DT:[278..283] Lluis) (NNP:[284..285] F) (,:[285..286] ,)
        (DT:[287..292] Farre) (NNP:[293..294] A) (,:[294..295] ,)
        (NNP:[296..303] Capella) (NNP:[304..306] G.)))

;section 3 Span:310..436
;Department of Clinical Biochemistry, Hospital de la Santa Creu i Sant Pau, 
;Antoni M. Claret, Barcelona, Spain. lig@santpau.es
(SEC
  (FRAG (NNP:[310..320] Department) (IN:[321..323] of) (NNP:[324..332] Clinical)
        (NNP:[333..345] Biochemistry) (NNP:[345..346] ,)
        (NNP:[347..355] Hospital) (IN:[356..358] de) (DT:[359..361] la)
        (NNP:[362..367] Santa) (NNP:[368..372] Creu) (NNP:[373..374] i)
        (NNP:[375..379] Sant) (NNP:[380..383] Pau) (,:[383..384] ,)
        (NNP:[386..392] Antoni) (NNP:[393..395] M.) (NNP:[396..402] Claret)
        (,:[402..403] ,) (NNP:[404..413] Barcelona) (,:[413..414] ,)
        (NNP:[415..420] Spain) (.:[420..421] .) ('':[422..436] lig@santpau.es)))

;sentence 4 Span:440..523
;Detection of K-ras mutations may be useful in the evaluation of pancreatic 
;cancer.
;[453..458]:gene-rna:"K-ras"
;[504..522]:malignancy:"pancreatic  cancer"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[440..449] Detection))
      (PP (IN:[450..452] of)
        (NP (NN:[453..458] K-ras) (NNS:[459..468] mutations))))
    (VP (MD:[469..472] may)
      (VP (VB:[473..475] be)
        (ADJP-PRD (JJ:[476..482] useful)
          (PP (IN:[483..485] in)
            (NP
              (NP (DT:[486..489] the) (NN:[490..500] evaluation))
              (PP (IN:[501..503] of)
                (NP (JJ:[504..514] pancreatic) (NN:[516..522] cancer))))))))
    (.:[522..523] .)))

;sentence 5 Span:524..862
;The aim of this study was to assess, in a prospective design, the  diagnostic
;utility of K-ras mutation analysis in 62 consecutive fine-needle  aspirates
;of pancreatic masses, using two PCR-based techniques-standard and 
;enriched-with detection limits of a mutant allele in the presence of 10(2) or
; 10(3) wild-type alleles, respectively.
;[613..618]:gene-rna:"K-ras"
;[681..698]:malignancy:"pancreatic masses"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[524..527] The) (NN:[528..531] aim))
      (PP (IN:[532..534] of)
        (NP (DT:[535..539] this) (NN:[540..545] study))))
    (VP (VBD:[546..549] was)
      (S-NOM-PRD
        (NP-SBJ (-NONE-:[549..549] *))
        (VP (TO:[550..552] to)
          (VP (VB:[553..559] assess) (,:[559..560] ,)
            (PP (IN:[561..563] in)
              (NP (DT:[564..565] a) (JJ:[566..577] prospective)
                  (NN:[578..584] design)))
            (,:[584..585] ,)
            (NP
              (NP (DT:[586..589] the) (JJ:[591..601] diagnostic)
                  (NN:[602..609] utility))
              (PP (IN:[610..612] of)
                (NP (NN:[613..618] K-ras) (NN:[619..627] mutation)
                    (NN:[628..636] analysis))))
            (PP (IN:[637..639] in)
              (NP
                (NP (CD:[640..642] 62) (JJ:[643..654] consecutive)
                  (NML (JJ:[655..659] fine) (HYPH:[659..660] -)
                       (NN:[660..666] needle))
                  (NNS:[668..677] aspirates))
                (PP (IN:[678..680] of)
                  (NP (JJ:[681..691] pancreatic) (NNS:[692..698] masses)))))
            (,:[698..699] ,)
            (S-MNR
              (NP-SBJ (-NONE-:[699..699] *))
              (VP (VBG:[700..705] using)
                (NP
                  (NP (CD:[706..709] two)
                    (ADJP (NN:[710..713] PCR) (HYPH:[713..714] -)
                          (VBN:[714..719] based))
                    (NNS:[720..730] techniques))
                  (::[730..731] -)
                  (NP (JJ:[731..739] standard) (CC:[740..743] and)
                      (VBN:[745..753] enriched)))
                (::[753..754] -)
                (PP (IN:[754..758] with)
                  (NP
                    (NP (NN:[759..768] detection) (NNS:[769..775] limits))
                    (PP (IN:[776..778] of)
                      (NP
                        (NP (DT:[779..780] a) (JJ:[781..787] mutant)
                            (NN:[788..794] allele))
                        (PP (IN:[795..797] in)
                          (NP
                            (NP (DT:[798..801] the) (NN:[802..810] presence))
                            (PP (IN:[811..813] of)
                              (NP
                                (NP (CD:[814..819] 10-LRB-2-RRB-)
                                  (NML-1 (-NONE-:[819..819] *P*)))
                                (CC:[820..822] or)
                                (NP (CD:[824..829] 10-LRB-3-RRB-)
                                  (NML-1 (JJ:[830..834] wild)
                                         (HYPH:[834..835] -)
                                         (NN:[835..839] type)
                                         (NNS:[840..847] alleles)))))))))))
                (,:[847..848] ,)
                (ADVP (RB:[849..861] respectively))))))))
    (.:[861..862] .)))

;sentence 6 Span:863..919
;Cytology alone offered a diagnostic  sensitivity of 75%.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[863..871] Cytology))
      (ADVP (RB:[872..877] alone)))
    (VP (VBD:[878..885] offered)
      (NP
        (NP (DT:[886..887] a) (JJ:[888..898] diagnostic)
            (NN:[900..911] sensitivity))
        (PP (IN:[912..914] of)
          (NP (CD:[915..917] 75) (NN:[917..918] %)))))
    (.:[918..919] .)))

;sentence 7 Span:920..1069
;The enriched higher sensitivity detection technique, in  combination with
;cytology, offered a diagnostic sensitivity of 91% without false  positives.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[920..923] The) (VBN:[924..932] enriched)
        (ADJP (JJR:[933..939] higher) (NN:[940..951] sensitivity))
        (NN:[952..961] detection) (NN:[962..971] technique))
      (,:[971..972] ,)
      (PP (IN:[973..975] in)
        (NP
          (NP (NN:[977..988] combination))
          (PP (IN:[989..993] with)
            (NP (NN:[994..1002] cytology))))))
    (,:[1002..1003] ,)
    (VP (VBD:[1004..1011] offered)
      (NP
        (NP (DT:[1012..1013] a) (JJ:[1014..1024] diagnostic)
            (NN:[1025..1036] sensitivity))
        (PP (IN:[1037..1039] of)
          (NP (CD:[1040..1042] 91) (NN:[1042..1043] %)))
        (PP (IN:[1044..1051] without)
          (NP (JJ:[1052..1057] false) (NNS:[1059..1068] positives)))))
    (.:[1068..1069] .)))

;sentence 8 Span:1070..1177
;The molecular analysis would have contributed to diagnosis in an  additional
;14 cases of pancreatic cancer.
;[1159..1176]:malignancy:"pancreatic cancer"
(SENT
  (S
    (NP-SBJ (DT:[1070..1073] The) (JJ:[1074..1083] molecular)
            (NN:[1084..1092] analysis))
    (VP (MD:[1093..1098] would)
      (VP (VB:[1099..1103] have)
        (VP (VBN:[1104..1115] contributed)
          (PP (TO:[1116..1118] to)
            (NP (NN:[1119..1128] diagnosis)))
          (PP (IN:[1129..1131] in)
            (NP
              (NP (DT:[1132..1134] an) (JJ:[1136..1146] additional)
                  (CD:[1147..1149] 14) (NNS:[1150..1155] cases))
              (PP (IN:[1156..1158] of)
                (NP (JJ:[1159..1169] pancreatic) (NN:[1170..1176] cancer))))))))
    (.:[1176..1177] .)))

;sentence 9 Span:1178..1252
;The standard technique contributed to  diagnosis in an additional 9 cases.
(SENT
  (S
    (NP-SBJ (DT:[1178..1181] The) (JJ:[1182..1190] standard)
            (NN:[1191..1200] technique))
    (VP (VBD:[1201..1212] contributed)
      (PP (TO:[1213..1215] to)
        (NP (NN:[1217..1226] diagnosis)))
      (PP (IN:[1227..1229] in)
        (NP (DT:[1230..1232] an) (JJ:[1233..1243] additional)
            (CD:[1244..1245] 9) (NNS:[1246..1251] cases))))
    (.:[1251..1252] .)))

;sentence 10 Span:1253..1413
;These results strongly support the use of  the enriched method of detecting
;K-ras mutations as a complement to cytology in  the evaluation of pancreatic
;masses.
;[1329..1334]:gene-rna:"K-ras"
;[1395..1412]:malignancy:"pancreatic masses"
(SENT
  (S
    (NP-SBJ (DT:[1253..1258] These) (NNS:[1259..1266] results))
    (ADVP (RB:[1267..1275] strongly))
    (VP (VBP:[1276..1283] support)
      (NP
        (NP (DT:[1284..1287] the) (NN:[1288..1291] use))
        (PP (IN:[1292..1294] of)
          (NP
            (NP (DT:[1296..1299] the) (VBN:[1300..1308] enriched)
                (NN:[1309..1315] method))
            (PP (IN:[1316..1318] of)
              (S-NOM
                (NP-SBJ (-NONE-:[1318..1318] *))
                (VP (VBG:[1319..1328] detecting)
                  (NP (NN:[1329..1334] K-ras) (NNS:[1335..1344] mutations)))))))
        (PP (IN:[1345..1347] as)
          (NP
            (NP (DT:[1348..1349] a) (NN:[1350..1360] complement))
            (PP (TO:[1361..1363] to)
              (NP (NN:[1364..1372] cytology))))))
      (PP (IN:[1373..1375] in)
        (NP
          (NP (DT:[1377..1380] the) (NN:[1381..1391] evaluation))
          (PP (IN:[1392..1394] of)
            (NP (JJ:[1395..1405] pancreatic) (NNS:[1406..1412] masses))))))
    (.:[1412..1413] .)))

;section 11 Span:1417..1461
;PMID: 9799749 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1417..1421] PMID) (::[1421..1422] :) (CD:[1423..1430] 9799749)
        (IN:[1431..1432] -LSB-) (NNP:[1432..1438] PubMed) (HYPH:[1439..1440] -)
        (JJ:[1441..1448] indexed) (IN:[1449..1452] for)
        (NNP:[1453..1461] MEDLINE-RSB-)))
